Resveratrol Drug Interactions: CYP Enzymes, Blood Thinners & Medicines

Resveratrol can interact with medicines. The strongest direct human evidence is pharmacokinetic: controlled studies show that supplemental resveratrol can alter the activity of several cytochrome P450 enzymes that metabolize prescription drugs. At 1 gram/day for four weeks, a healthy-volunteer study found inhibition of CYP3A4, CYP2D6 and CYP2C9 and increased CYP1A2 activity. A separate human study found a CYP2E1 interaction signal, and another reported altered carbamazepine pharmacokinetics after resveratrol pretreatment.

That does not mean resveratrol is dangerous with every medicine. It means “it is only a supplement” is not a safe interaction strategy.

Resveratrol interaction evidence at a glance

Pathway / concern	Human evidence	Practical meaning
CYP3A4	Activity inhibited in a 1 g/day healthy-volunteer study; carbamazepine PK also altered in a separate study	Potential to change exposure to CYP3A4 substrates.
CYP2D6	Activity inhibited after 1 g/day for 4 weeks	Relevant because many drugs depend partly on CYP2D6 metabolism.
CYP2C9	Activity inhibited after 1 g/day for 4 weeks	Potential concern for narrow-therapeutic-index CYP2C9 substrates.
CYP1A2	Activity increased in the same human enzyme study	Direction of interaction can differ by enzyme; not all effects are inhibition.
CYP2E1	500 mg/day pretreatment altered chlorzoxazone metabolism in 12 volunteers	Supports a human CYP2E1 interaction signal, though clinical significance for other drugs is uncertain.
Platelets / bleeding	Biological plausibility and preclinical evidence; clinical interaction magnitude not well quantified	Extra caution with anticoagulants, antiplatelet drugs and surgery.

Why resveratrol can interact with medication

Many drugs are cleared by enzymes in the liver and intestine. If a supplement inhibits one of those enzymes, a medication can sometimes remain in circulation longer or reach a higher exposure. If the supplement induces or increases enzyme activity, the opposite can occur: a drug may be cleared faster.

Resveratrol is especially important because this is not only a test-tube concern. Human intervention studies have measured changes in enzyme activity after supplementation.

The strongest human CYP study

In a prospective study of 42 healthy volunteers, participants took 1 gram of resveratrol daily for four weeks. Researchers used probe drugs to phenotype several drug-metabolizing enzymes before and after supplementation.

The study reported:

• CYP3A4 inhibition
• CYP2D6 inhibition
• CYP2C9 inhibition
• increased CYP1A2 activity

This is unusually useful supplement-interaction evidence because it directly measured enzyme activity in people rather than assuming an interaction from cultured cells.

The limitation is equally important: the study used 1 g/day and measured enzyme phenotypes, not clinical toxicity from dozens of co-administered medications. It therefore establishes interaction potential, not a precise risk estimate for every lower dose or every drug.

Resveratrol and CYP3A4

CYP3A4 metabolizes a very large number of medicines. Because resveratrol inhibited CYP3A4 activity in the 2010 human study, drugs that depend heavily on this pathway deserve extra attention.

A separate human pharmacokinetic study strengthened the concern by examining carbamazepine, a drug whose metabolism involves CYP3A4. Resveratrol pretreatment altered carbamazepine pharmacokinetics in healthy volunteers.

This does not justify predicting the exact effect on every CYP3A4 substrate. Drugs differ in therapeutic window, alternate clearance pathways, dose and sensitivity to enzyme changes.

Resveratrol and CYP2C9

CYP2C9 is clinically important because it participates in the metabolism of several medicines, including drugs for which relatively small exposure changes can matter. The human 1 g/day study found CYP2C9 inhibition.

For someone using a narrow-therapeutic-index CYP2C9 substrate, the correct response is not to guess a “safe separation time” between the supplement and medicine. Enzyme modulation can persist beyond the few hours when a capsule is physically in the stomach.

Resveratrol and CYP2D6

CYP2D6 activity was also inhibited in the healthy-volunteer study. CYP2D6 is involved in the metabolism or activation of many medicines, and genetic differences already make this pathway highly variable between people.

Adding an inhibitor can therefore be more relevant in some individuals than others. A generic interaction checker cannot always predict the magnitude without knowing the drug, dose, genotype, other medicines and clinical context.

Resveratrol and CYP1A2

The same human trial found increased CYP1A2 activity, which is an important reminder that resveratrol does not simply “block liver enzymes.” It can affect different enzymes in different directions.

CYP1A2 participates in the handling of caffeine and multiple medicines. However, the study does not establish that resveratrol will produce a clinically meaningful interaction with every CYP1A2 substrate.

Resveratrol and CYP2E1

A 2016 open-label sequential study tested 12 healthy volunteers using chlorzoxazone as a CYP2E1 probe. Participants received 500 mg/day resveratrol for 10 days. Resveratrol pretreatment reduced CYP2E1-mediated chlorzoxazone metabolism.

This is a direct human signal, but the sample was very small and the study did not determine clinical risk for every other CYP2E1 substrate.

Resveratrol and carbamazepine

Carbamazepine is one of the clearest examples where a resveratrol-drug interaction has been studied directly rather than inferred from an enzyme assay. A human pharmacokinetic study reported altered carbamazepine exposure after resveratrol pretreatment.

If you take carbamazepine, concentrated resveratrol supplementation should be discussed with the prescriber or pharmacist rather than added casually. Carbamazepine dosing is clinically managed, and changes in exposure can matter.

Resveratrol and blood thinners

Resveratrol can affect platelet-related biology in experimental research, creating a plausible concern when it is combined with medicines that reduce clotting. The magnitude of this interaction at ordinary supplement doses has not been defined by large clinical trials.

That means two extremes are both inappropriate:

• “Resveratrol definitely causes dangerous bleeding with all blood thinners.” — too strong.
• “There is no interaction because it is natural.” — also unsupported.

People taking warfarin, direct oral anticoagulants, aspirin, clopidogrel or multiple agents that increase bleeding risk should have the combination reviewed professionally.

Can you take resveratrol with aspirin?

There is no large trial establishing a universal safe or unsafe resveratrol-plus-aspirin dose. Because both can influence platelet-related pathways, combined use deserves caution—particularly in people with prior bleeding, peptic-ulcer disease, anticoagulant use or upcoming surgery.

Resveratrol and diabetes medication

Some resveratrol trials report modest effects on glucose or insulin-related endpoints. If a person already uses glucose-lowering medication, there is a theoretical possibility of additive glucose lowering even though average clinical effects of resveratrol are inconsistent.

Do not reduce prescribed medication based on supplement use. The larger issue is that resveratrol has not shown sufficiently reliable glycemic efficacy to justify self-directed medication substitution.

Resveratrol and blood-pressure medicines

Meta-analyses report small average reductions in blood pressure in some populations. For people already taking antihypertensive drugs, additive effects are possible, but the magnitude is not predictable from population averages.

Dizziness, faintness or unusually low blood pressure after adding a supplement should not be ignored.

Resveratrol and tamoxifen or other hormone-sensitive therapies

Resveratrol has estrogen-related and enzyme-related activity in experimental systems, but direct clinical interaction evidence for specific hormone-sensitive therapies is limited. This is exactly the kind of situation where mechanism alone should not be converted into a confident yes/no answer.

People receiving cancer therapy or endocrine therapy should have supplements reviewed by the oncology team because treatment efficacy can depend on exposure, metabolism and disease context.

Does taking resveratrol at a different time prevent an interaction?

Not necessarily. Separating a supplement from a medicine by two or four hours can help with some gut-level binding interactions, but CYP enzyme modulation is different. If resveratrol changes enzyme activity, simply taking it at breakfast and the medicine at dinner may not eliminate the interaction.

Do lower resveratrol doses eliminate interaction risk?

The best human enzyme study used 1 g/day, and the CYP2E1 study used 500 mg/day. It is reasonable to expect dose to influence interaction magnitude, but there is not enough clinical evidence to define a universal dose below which interactions become impossible.

Product formulation matters too. A 2025 pharmacokinetic crossover study showed that oral formulations can produce substantially different resveratrol exposure. A lower label dose with much higher systemic exposure could theoretically behave differently from a poorly absorbed formulation.

Who should get a medication review before taking resveratrol?

• Anyone taking a drug with a narrow therapeutic index.
• People taking carbamazepine.
• People taking anticoagulant or antiplatelet therapy.
• People taking multiple prescriptions metabolized through CYP3A4, CYP2D6, CYP2C9, CYP1A2 or CYP2E1.
• People receiving cancer therapy, transplant medication, antiarrhythmics, seizure medication or immunosuppressive therapy.
• People preparing for surgery.
• Anyone who develops a new adverse effect after adding resveratrol to an otherwise stable medication regimen.

What this page cannot do

This is an evidence map, not a personalized interaction checker. A CYP enzyme can be involved in hundreds of drugs, and knowing that resveratrol affects an enzyme does not tell us the exact effect size for every substrate.

The practical decision depends on the specific medicine, dose, therapeutic window, reason for treatment, other drugs and supplements, kidney/liver function and resveratrol formulation.

Bottom line

Resveratrol has real human pharmacokinetic interaction evidence. The clearest data show modulation of CYP3A4, CYP2D6, CYP2C9, CYP1A2 and CYP2E1, plus a direct pharmacokinetic interaction signal with carbamazepine.

That does not make resveratrol incompatible with all medication. It does mean prescription-drug users should not assume that a concentrated polyphenol is metabolically inert.

For the broader safety context, read Resveratrol Side Effects and Resveratrol Dosage. For all source records, see the Resveratrol Data Center.